

Company registration number: 08116159
Charity registration number: 1148845

**ALEX'S WISH
TRUSTEES' REPORT AND
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025**

**Alex's Wish
Contents**

	Page
Trustees' Report	1—17
Independent Examiner's Report	18
Statement of Financial Activities (including Income and Expenditure Account)	19
Balance Sheet	20
Notes to the Financial Statements	21—26
The following pages do not form part of the statutory accounts:	
Detailed Statement of Financial Activities (including Income and Expenditure Account)	27—28

The trustees present their report and the financial statements for the year ended 30 June 2025.

Objectives and Activities

Aims and Objectives

1. The principal objects of the charitable company are the relief of sickness and the preservation of good health by supporting scientific research into the improved diagnosis, prevention, or treatment of Duchenne Muscular Dystrophy by:

- a) Extending the current scope of drugs / treatments so that they will help all children with Duchenne Muscular Dystrophy.
- b) Fund first stage clinical trials that provide the safety and efficacy of some of these treatments and then progress this into larger scale production.
- c) Fund the completion of scientific work already begun, to bring it to clinical trials, and fund other forms of treatment that will work on all children regardless of their genetic mutation.
- d) Fund studies that will bring about data and information to help decision makers make decisions on which treatments to bring to market.
- e) Fund the DMD Care programme empowering patients/families to access the best care wherever they live in the UK.
- f) Fund new technological advances to help children and young adults living with Duchenne live a better quality of life.

2. Advance the education of the public in all areas relating to Duchenne Muscular Dystrophy by disseminating information on the disease and its treatments and cures. To:

- a) Disseminate information using online and offline materials, including the Alex's Wish Website and via our monthly e-newsletters to our supporters.
- b) Running events and fundraising activities, including our Spring Launch and Autumn Lunch which sees our team, trustees, representatives from Duchenne UK, and our supporters come together for us to share our impact during the last 12 months and our plans.
- c) Promoting our work across a variety of social media platforms, including Facebook, You Tube, LinkedIn, Instagram and Tik Tok.
- d) We have built great relationships with the local media outlets in our region including ITV Central and BBC East Midlands and regularly generate news articles and updates in local newspapers, including The Leicester Mercury, The Loughborough Echo and local magazines posted through doors. We appear regularly on the local radio stations including BBC Radio Leicester to raise awareness about Duchenne and the impact this has on families living with it.
- e) Talking and presenting at various events on Corporate Social Responsibility, the impact of living with Duchenne Muscular Dystrophy and About Alex's Wish - it is important our personal story is shared amongst others to be the voice for other families affected by Duchenne.
- f) Owning It 'The Power of Resilience' talks and workshops delivered to businesses in exchange for a donation to the charity.

Significant Activities

Statement from the CEO and Charity Founder, Emma Hallam

Dear Supporters,

Since we launched Alex's Wish in late 2012, after our son Alex was diagnosed with Duchenne Muscular Dystrophy, we continue to make great progress. Our relentless energy and passion inspire us every single day, to deliver results for the Duchenne community.

We exist to defeat Duchenne for this generation of children and young adults. Our approach is simple, fund the best science, support practical clinical trials and make sure children and young adults living with Duchenne in the UK, can access treatments, new technologies and care, wherever they live.

...CONTINUED

**Alex's Wish
Trustees' Report (continued)
For The Year Ended 30 June 2025**

Significant Activities - continued

We fund across the treatment journey – from research to real-world care. This includes projects ranging from gene therapy and gene editing, stem cell therapy, heart research and early detection, steroid optimisation and alternatives, clinical care and improving access to clinical trials in the UK, improving quality of life through new technologies – namely The ELEVEEX Suit and The DREAM Wheelchair, as well as supporting female carriers through better understanding the impact this has for them.

Since launch, we have delivered:

- Raised over £2.8M
- Funded 42 projects
- Supported 24 medical research projects
- Supported 4 clinical trials
- Supported 5 projects improving care in the UK
- Supported 7 clinical posts supporting the Duchenne community
- Supported 2 technology projects to improve how children and young adults navigate the world whilst living with Duchenne

How we decide what to fund. Every project is reviewed by an independent Scientific Advisory Board, made up of leading global experts in Duchenne. This ensures that funding only goes to the best science worldwide. No duplication of existing research. Every project has a clear path of delivery. Treatments move faster from the lab to the patient. We work closely with Duchenne UK, to maximise impact and accelerate progress.

How we got here. Alex's Wish was founded by Emma and Andy Hallam after their son Alex was diagnosed with Duchenne shortly before his fourth birthday.

At the time, support was limited. We were told to take Alex home and live the best life possible. Long-term steroids were the only treatment option offered, despite significant side effects. There was no cure, and little hope of medical breakthroughs.

Since Alex's diagnosis in 2010, Emma and a small, dedicated team – supported by an incredible community of trustees, ambassadors, supporters, and partners – have worked tirelessly to create real, measurable change.

Alex has played his part too, spending much of his young life taking part in clinical trials that have helped advance treatments and deliver genuine progress.

We're deeply grateful to everyone who helps make progress possible.

An exciting time in medical breakthroughs

The science is at a very exciting time; a time of optimism as new treatments have emerged, one of which is proving to be delaying disease progression. We are aware that time is not on our side, and that for families affected by Duchenne – whether they have a child diagnosed several years ago, or families receiving a recent diagnosis – they need solutions to support their child. This is what drives us every single day, to fundraise and raise awareness to continue supporting new innovative projects to address the problems within the Duchenne community. This financial year, we have been able to support a further four projects.

Vamorolone (a steroid alternative drug)

2023 was a breakthrough year – the first ever drug approved for use on children with Duchenne – called Vamorolone, thanks to charities like Alex's Wish who helped fund the early stages of this project. When Alex was diagnosed back in 2010, we were told the standard medication for children with Duchenne, steroids, would keep them independently mobile for longer, but with harmful side effects. Vamorolone a new steroid drug, that has less harmful side-effects to traditional steroids, has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. We are incredibly proud that we were able to invest in the early stages to make this a reality – proof that Alex's Wish is a charity that is making a positive impact for this generation of children and young adults living with Duchenne.

...CONTINUED

Significant Activities - continued

Givinostat (proving to delay disease progression)

2024 was another breakthrough year – Givinostat, a drug to help delay disease progress has been conditionally approved in the UK by MHRA, but it is not yet readily available through the NHS. It is an 'HDAC inhibitor', it blocks enzymes called histone deacetylases, which are involved in turning genes 'on' and 'off' within cells to help reduce inflammation and muscle loss. Work is underway to hopefully get this drug approved by NICE so that every child and young adult living with Duchenne can access this drug through the NHS. In the meantime, this drug has been offered free of charge in the UK through the early access programme. However, it has been the decision of each hospital trust to decide whether they will provide it to their Duchenne community. Some have, and some still haven't, Duchenne UK and the Duchenne community has been working incredibly hard campaigning for access across the UK. We have been supporting NICE as a patient representative, offering insights into why gaining access to this drug is so important. Whilst Alex's Wish did not directly financially contribute towards this project, as a family we have been taking part in the clinical trial over several years.

Gene Therapy

We were told that Gene Therapy wouldn't happen in our son's lifetime. During the time that Alex's Wish has been in operation, we supported Solid Biosciences, a start-up to pursue this new technology, and boys are now being dosed with gene therapy in clinical trials taking place now in the UK. We know there are challenges with Gene Therapy, which is why we are continuing to support projects that are looking to address these problems – and bring better therapies to our children.

Best practice in Duchenne care

We are working alongside DMD Care UK, to help support better quality of care for everyone living with Duchenne in the UK. To date, we have funded several projects, including financial support for a DMD Hub Project Manager designed to increase clinical trial capacity in the UK and, a nutrition programme supporting those affected by Duchenne, and a project looking to address the lack of accessible housing amongst our community. This financial year, we have supported a transitioning project, supporting young adults living with Duchenne during the transitioning stage when they move from paediatric care into adult services – something which we have recently encountered ourselves with Alex.

We are incredibly positive about the future and Alex's Wish gives us hope. Duchenne Muscular Dystrophy is part of our lives, not out of choice, but we will make it as best as we can, and we will never stop our journey to conquering Duchenne.

I continue to support this important cause, by working **voluntarily** for the charity and as a very proud trustee and CEO – it is my pleasure to do this, to support all families affected by Duchenne.

Our work is only possible, thanks to our army of supporters, the charitable foundations who support us, the local business community, our business sponsors, our small team, our patron, ambassadors and our dedicated trustees and we would like to thank every single one of them.

Thanks for everything you do.

Emma Hallam
Charity Founder and CEO

Public Benefit

The Charity has established its grant making policy to achieve its objectives for the public benefit to find a cure for Duchenne Muscular Dystrophy and to slow down the rate of progression by maintaining muscle strength for longer, leading to increased life expectancy as well as a better quality of life.

We only want to fund great science - projects that can improve the knowledge base and bring treatments that can reach the clinic and improve the lives of boys with Duchenne Muscular Dystrophy in many ways. We want to fund new technologies that will go on to help those affected by Duchenne, by making the world accessible to them.

...CONTINUED

**Alex's Wish
Trustees' Report (continued)
For The Year Ended 30 June 2025**

Public Benefit - continued

We formed a partnership with Duchenne UK. Duchenne UK share the same mission and objectives as Alex's Wish and are also a parent-led charity. As a Charity Partner to Duchenne UK, we receive projects that require co-funding. All such projects have been reviewed extensively by their Scientific Advisory Board (SAB) which is made up of some of the world's leading experts in Duchenne Muscular Dystrophy. They bring with them a wide range of essential skills and knowledge basis including scientific, clinical and drug discovery and development. When scientists approach Duchenne UK with their ideas for new research projects it is the SAB who apply their experience and expertise to test these ideas, helping to refine them, if necessary, in order that Duchenne UK can make informed decisions on funding. Alex's Wish Trustees review all projects put forward before deciding upon specific projects to fund.

We regularly send updates on project performance and outcomes to our supporters through a monthly e-newsletter as well as publish updates on our social media channels, news articles on our website and submit press releases to the local media companies. We have appeared on BBC East Midlands Today and ITV Central.

The trustees confirm that they have complied with the requirements of Section 17 of the Charities Act 2011 to have due regard to the Charity Commission's guidance on public benefit.

Achievements and Performance

Main Achievements

About Duchenne

Duchenne in numbers

- 1 of the most serious genetic diseases in children
- 1 in 3,500 boys born with Duchenne worldwide
- 2,500 boys affected in the UK (approx.)
- 300,000 boys affected globally (approx.)
- 2 families every week receive a diagnosis in the UK
- 12 is the average age boys require a wheelchair in 90% of cases

About Duchenne

Duchenne Muscular Dystrophy is a severe, progressive genetic condition that primarily affects boys. Duchenne crosses all races, cultures, and backgrounds. Girls can also be affected and make up around 1% of diagnoses.

What causes Duchenne?

Duchenne is caused by a genetic mutation that stops the body from producing dystrophin, a protein essential for healthy muscle function.

Without dystrophin:

Muscles weaken and break down over time
Muscles cannot repair themselves properly
Strength, movement, and independence are progressively lost
Around one in three cases occurs in families with no previous history of Duchenne.

Early signs and diagnosis:

The average age of diagnosis is around four years old.

- Delays in sitting and walking
- Difficulty keeping up with peers
- Speech delay or frequent falls

...CONTINUED

Main Achievements - continued

How Duchenne progresses:

Duchenne affects everyone differently – even siblings with the same genetic mutation can experience very different progression.

- Muscle weakness usually begins in early childhood, affecting the hips, thighs, shoulders, and pelvis
- During the teenage years, weakness spreads to the arms, lower legs and trunk
- Because dystrophin is also missing from the heart and lung muscles, breathing and heart function are affected
- Some individuals may experience learning and/or behavioural challenges
- Ventilation support and 24-hour care is needed as the disease progresses

With improved care, many people with Duchenne are now living into their 20s and 30s, and ongoing research and clinical trials continue to improve quality of life and outcomes.

Our Vision

Our Vision is a world without Duchenne Muscular Dystrophy.

We want a future that stops the devastating impact Duchenne has on our children and young adults, a future where they can grow and prosper and fulfil their dreams.

A life where they can enjoy every day without the fear of the progression this muscle wasting disease has on their bodies. A future without Duchenne would be a bright and happy future for all those affected. We need to act quickly to save this generation. Doing nothing is not an option. Our boys and their families need to live without fear and have hope for the future.

Our Mission

Alex's Wish exists to end Duchenne for this generation.

We do this by halting and reversing muscle wasting through funding groundbreaking clinical trials, supporting world-class care, and accelerating access to life-enhancing technologies across the UK.

Our mission is inspired by Alex – a calm, quietly determined and courageous young man living with Duchenne. For more than a decade, Alex has taken part in clinical trials, helping bring vital treatments closer to the families who need them.

His resilience drives our **Be More Alex mindset**: a can-do philosophy captured in one simple idea – when the world gives you lemons, make lemon meringue pie.

Our Philosophy

Be More Alex runs through everything we do to raise funds and awareness – from our fun, community-powered signature events, to our “push-yourself” personal challenges.

It's more than a strapline; it's a mindset that turns adversity into action.

Be More Alex brings the joy: gratitude for what we have, optimism for what's possible, and the strength of a like-minded community determined to squeeze every last drop out of life.

Our Values

We lead with a positive, can-do mindset.

If Alex can stay positive while living with Duchenne, so can we.

Our focus is on what's possible and acting on what we can control.

...CONTINUED

**Alex's Wish
Trustees' Report (continued)
For The Year Ended 30 June 2025**

Main Achievements - continued

Collaboration

We're stronger together. By working with families, supporters, and partners like Duchenne UK, we achieve more and create greater impact.

Inspire and Educate

We tell it like it is. We're open, honest, and real about life with Duchenne - using our positive voice to inspire action, raise awareness, and empower others to join the mission.

Family-focused

People come first. We value time, flexibility and balance, and we deeply appreciate the commitment of our family of trustees, ambassadors, volunteers and supporters.

Ambitious

We're in it to change history. We act with urgency, think big, and push for real change – determined to defeat Duchenne for this generation.

Our Impact this year

The Trustees are delighted to have been able to make significant payments during this accounting period to four projects equating to £232,989 in line with its objectives. We provide project updates as and when they become available on our website alexswish.org, e-newsletters to our supporters and at our supporter events – namely our Spring Lunch and Autumn Launch.

• Given an additional £40,000 towards the 'Help the Heart' Cardiac Grant Call.

Last year we gave £63,000, and this financial year, we have given another £40,000 towards this important project. Our heart muscles need dystrophin to function efficiently. In Duchenne, a lack of dystrophin means that heart muscles weaken over time. Heart cells are replaced by scar and fatty tissue, which leads to a type of heart muscle disease called dilated cardiomyopathy. The age when this happens in Duchenne can vary from person to person, from early childhood to adulthood. Children with Duchenne don't usually have cardiac symptoms. However, weakening heart muscles are part of the natural progression of the disease. Therefore, early monitoring, preventative treatment, and ongoing management are important for keeping the heart healthy into adulthood. It is currently not possible to prevent heart weakness in Duchenne completely. However, steroids and heart medication can slow down the decline in heart function.

This grant call will help us understand how the heart is affected and identify potential innovative treatment strategies and approaches. In response to a huge unmet need in cardiac management and effective therapeutic options targeted to at the heart, leading to poor outcomes in people living with Duchenne. This is an area of focus for us and thrilled to share that two cardiac projects are now pushing forward, as follows: One in **repurposing Empagliflozin for Duchenne** and the other an **international survey on clinical presentation and service provision to inform ongoing care**.

Thanks to The Nottingham Hot Property Show for donating £36,000 towards these projects.

Project 1 - Repurposing Empagliflozin for Duchenne

Institution: Great Ormond Street Hospital

Principal Investigator: Sebastiano Lava

Status: Ongoing until March 2028

...CONTINUED

**Alex's Wish
Trustees' Report (continued)
For The Year Ended 30 June 2025**

Main Achievements - continued

Among the recent improvements in adult heart failure management, the sodium glucose type 2 inhibitor (SGLT2) empagliflozin was found to reduce cardiovascular death or heart failure by 25%. However, little is known on its use in children or adolescents with Duchenne. Current heart failure therapy in children is unsatisfactory and heart failure trials in children have historically often failed because the right dose was not used or inappropriate formulations of the drug and clinical endpoints were adopted in the trials. We have funded this project, enabling the team to explore whether this drug can be repurposed for the Duchenne heart in a clinical study which addresses all the limitations above. If the optimal dose is confirmed and early efficacy signals are detected in this pilot study, this will allow for a larger study to demonstrate the benefit of this therapy of Duchenne-associated cardiomyopathy.

Project 2 – An international survey on clinical presentation and service provisions to inform care
Institution: The University of Newcastle
Principal Investigator: Michela Guglieri
Status: Ongoing

Historically, research into female carriers of dystrophinopathies, who are women that have a genetic mutation of the dystrophin gene on one of their x chromosomes, has been low priority and we want to change this.

Duchenne female carriers can be subject to symptoms of Duchenne such as muscle weakness and diseases of the heart, and more clinical research is needed to better understand how these individuals can be better supported and treated. We are supporting a team as they lead the development of a survey which aims to gain deeper insights into the clinical signs and symptoms that are observed by medical professionals which show what being a carrier looks like, how carriers health is tested and observed, (specifically heart and muscle health), how genetic risks are managed and addressed, and the impact of caring for an affected person on physical symptoms and mental health. The results of the survey will inform a much-needed natural history study, develop a more targeted survey to circulate to individuals tested for carrier status, in collaborations with large genetic centres and match with cardiac guidance as part of the DMD Care UK.

• Given £168,000 towards an Innovative Medical Grant Call

Institution: Myogene
Principal Investigator: Courtney Young, Co-Founder and CEO of MyoGene Bio
Status: Ongoing

We are proud to have supported a project with MyoGene Bio, a San Diego-based biotech company dedicated to developing transformative therapies for muscle disease, to accelerate development of an innovative gene editing therapy for Duchenne Muscular Dystrophy. The project entitled 'Optimization of a gene editing therapy' will focus on refining MyoGene's cutting-edge CRISPA/Cas 9-based therapy. MyoDys45-55 aims to permanently delete a mutation hotspot in the DMD gene, restoring the reading frame and enabling production of a shorter but functional dystrophin protein, like that found in individuals with Becker Muscular Dystrophy (a milder form of Muscular Dystrophy). The therapy offers several advantages over existing genetic medicines, including permanent DNA editing, preservation of natural gene regulation, and restoration of a dystrophin protein three times the size of micro-dystrophin.

If successful, the therapy could be suitable for approximately 50% of boys with Duchenne. The funding will enable MyoGene to optimise muscle targeting, assess durability and explore potential treatment regimens that could improve editing efficiency. The company has already engaged the FDA in the US to accelerate their ability to conduct a clinical trial in DMD boys, and all being well, they should be in the clinic in 2027.

Thanks to The Brothers Trust, who kindly gave a grant for £35,000 towards this project.

• Given £22,000 towards a transitioning of care project – better supporting standards of care for those transitioning from paediatric care to adult care

Institute: Leeds Teaching Hospital
Principal Investigator: Anne-Marie Childs
Status: Ongoing until September 2027

...CONTINUED

Main Achievements - continued

For young people living with Duchenne, the transition from paediatric to adult care is fraught with challenges. This transition period is a critical time, not just for medical management, but also for the psychosocial support these young individuals need to thrive as they move into adulthood. Sadly, this transition period often lacks the necessary structure and support, families are left navigating a fragmented healthcare system with varying levels of support across the country.

The consequences of not having a clear and well-supported transition pathway are severe. Without proper transition planning, young people often face abrupt changes in their care, leading to confusion, anxiety and in some cases deterioration in their health. Additionally, the variation in services across the country means that while some receive excellent care, others are left without the necessary resources and support, particularly when their condition becomes more complex.

To address these issues, we are working in collaboration with Duchenne UK and Joining Jack (another parent-led charity in the UK) towards developing a comprehensive transition pathway tailored specifically for young people with Duchenne. This project will create resources and support systems that ensure a smoother, more effective transition into adult care, providing both medical and psychosocial support.

By working together collaboratively with healthcare professionals, patients, and their families, this initiative will produce practical tools, guides, and models that can be implemented across different healthcare settings.

• Given £5,989 towards a Post BIND (The Brain Involvement in Dystrophinopathies) Co-ordinator

Institute: University College London
Principal Investigator: Francesc Muntoni, Paediatric Neurologist
Status: Ongoing until June 2026

This funding supports the Co-ordinator post for the Brain Involvement in Dystrophinopathies (BIND) consortium which brings together 19 partners from Europe and Japan who received funding for a 4-year project from the European Commission to address the preclinical and clinical aspects related to the role of dystrophin in the brain.

There is a wealth of data on gene mutation and clinical and imaging phenotypes that has not been fully analysed and published and this post was put in place in July 2024 to complete this work and to drive BIND's strategic aims, adding greatly to our knowledge and treatment options for the involvement of the brain in Duchenne. Several workshops and presentations were published in the summer of 2025 and the consortium remains committed to improving diagnosis and treatments of brain comorbidities in dystrophinopathies.

• We have continued to raise awareness about Duchenne Muscular Dystrophy.

Through regular posting across our social media platforms, about stories, progress, medical news, ways in which our supporters made an impact and how they can support us in the future and are seeing an ever increasing following and engagement online.

Thank you to everyone who follows our journey. Through our calendar of events, we have been raising the profile of our cause and engaging with existing and new supporters.

• We have secured a pipeline of fundraising support and activities over the next 12 months.

In addition to the funds received during this financial year, we have seen great success with our fundraising activities in the latter part of 2025 and into 2026.

We have secured funding from various trusts and foundations, including **The Brothers Trust, The Hospital Saturday Fund and The D'Oyly Carte Charitable Trust.**

Delivered a calendar of successful and profitable fundraising activities and events for our supporters to get involved with, so that we can continue to raise money to further our mission.

...CONTINUED

**Alex's Wish
Trustees' Report (continued)
For The Year Ended 30 June 2025**

Main Achievements - continued

Plus, much more about which you can find the details by following us across our social media platforms and on our website.

Recent activities and achievements

Over the years, we have funded a variety of projects across a broad-spectrum from early-stage research through to clinical trials, funded five clinical posts to support clinical trial development and patient access, funded DMD Care projects, as well as supported new technologies.

Here are some examples of the work we have funded over recent years.

• **The ELEVEX Suit - £198,090 funding given towards this project** - When a person loses their upper body function basic tasks like brushing their teeth, feeding themselves, or hugging family become impossible. Physical barriers and social barriers (assumptions about their role and value in society) restrict freedom.

Eventually, the barriers become insurmountable, removing the ability to live independently, continue in education, secure a job, or sustain a social life. A third of pupils aged 11-15 with a long-term illness, disability or medical condition said their disability negatively impacted their ability to participate in education.

Ultimately, they're removed from public life and become invisible, so too do their voice and needs. This must change. The ELEVEX Suit will give back what Duchenne steals from young people by restoring the use of their arms, the suit will transform disabled kids into independent teenagers living with dignity. It will transform their lives by ultimately delivering a measurable impact on inclusion, educational attainment, and participation in society at large. We are collaborating with Duchenne UK on this project, which is designed not just to benefit the UK, but worldwide, as well as other disease areas and conditions with loss of upper body function.

A dynamic and collaborative team are working on this project, comprising engineers, biomechanics experts, and control system specialists. Crucially, young people from the Duchenne and Spinal Muscular Atrophy communities have joined the design team and have actively shaped the latest concept development work, building on learning from previous prototypes. In 2025, user-centred product testing of several prototypes was conducted in the real world, and we are now at a stage where most of the key engineering challenges have been resolved. The next stage is to complete development of the final features of the mechanical architecture as well as the design. Following completion, the project will move into clinical evaluation, complete medical device certification and define the manufacturing process, aiming to ensure access to users as soon as possible.

We are extremely grateful to our wonderful supporters and to The Brothers Trust for their contributions towards this project, and at time of writing this report we can confirm further funding will be given in 2026.

• **Developing nutritional guidelines, resources and a structured nutritional programme - £50,865 given towards this project** - Obesity is a serious health complication in Duchenne, with negative implications on cardiac and respiratory function, mental health, and quality of life. Numerous factors contribute to weight gain, including limited physical activity and the use of long-term steroids. Whilst the need for better diet and nutritional management in boys with Duchenne is recognised, this aspect of care is not addressed in the NHS, due to lack of resources and specific guidance. The solution is to develop the evidence required to affect change in Duchenne weight management care and a range of resources, tailored to the needs of boys with Duchenne and their families, that they can access particularly after initiation of steroid treatment.

There is currently no structured nutritional and weight management guidance available to boys with Duchenne in the UK. A UK wide survey of families of boys showed that for 46% of patients, nutritional issues are not monitored or addressed in the clinic. The survey also highlighted that Duchenne specific nutritional and lifestyle advice is considered essential by these families. The 2018 international standards of care recommend that a registered dietician should assess nutritional status and create a specific nutritional plan, both of which are currently not available to UK patients through the NHS. Taken together, these highlight a major gap in UK care of boys with Duchenne, which we are uniquely placed to help address through DMD Care UK and funding this project. This project is ongoing, and the Nutrind study is up and running and recruiting, with the aim of identifying the caloric needs of both ambulant and non-ambulant boys on steroid therapy.

...CONTINUED

**Alex's Wish
Trustees' Report (continued)
For The Year Ended 30 June 2025**

Recent activities and achievements - continued

- **DMD Care UK project manager post at University of Newcastle** - DMD Care UK has now successfully opened working groups across all agreed standards of care. Each working group is working towards having published guidelines, endorsed by the relevant professional bodies – cardiac, respiratory, bone and endocrine. Patient and family guides have been produced in parallel with a publication of each clinical guideline and consultation with the Family Focus Group of DMD Care UK. This enables patients and families to better advocate for their care and to bring latest information to the attention of their clinical teams as well as to make informed choices about their care.

- **DMD Hub is a flagship project that has successfully expanded capacity for clinical trials for Duchenne treatments in the UK** - In the first four years of the project, Duchenne UK, and its partner charities (including Alex's Wish) invested £2.7m in the DMD Hub, with an additional £1.6m committed over the next 4 years. The DMD Hub is a collaboration between Duchenne UK, the John Walton Muscular Dystrophy Research Centre (JWMDRC) in Newcastle, and Great Ormond Street Hospital London. It was set up to expand clinical trial capacity and expertise and stop clinical trials being turned away from the UK. The project team developed the Clinical Trial Finder to help patients access information on DMD clinical trials in the UK.

We are pleased to share that since 2016, the DMD Hub has:

- Engaged with 15 companies and 4 Clinical Research Organisations
- Recruited 800 boys onto clinical trials
- Facilitated 57 clinical trials, 28 are currently active, 7 at feasibility stage and 4 in early discussions
- Provided 34 posts to facilitate the day to day and set up of new trials – 72% of these posts have been sustained
- Leveraged £1.3M of funding from other funders and industry to support DMD clinical research

- **Antifibrotic screening platform, University of Newcastle** - A new molecular biology technique which enables us to look inside muscle cells for Duchenne patients. This will help us to understand which treatments are most effective in preventing fibrosis, a process which happens when muscle cells die and are replaced by fatty tissue. Fibrosis can lead to failure of the heart and respiratory muscles, which is the most common cause of death in adults with Duchenne. While gene therapies could be transformative for people living with Duchenne, the progressive nature of the disease limits their impact. Combining gene therapies with drugs that could reduce muscle deterioration, such as anti-fibrotics could help to maximise the effect of these treatments. Anti-fibrotics could also be used to treat patients who are not eligible for gene therapy, and for those in the later stages of the disease. We funded a PhD post for 3 years, which concluded at the end of 2025, during this time the team has selected a short-list of potentially interesting compounds and were studying the effects of selected drugs, more work is ongoing, with results expected soon.

- **A pioneering Pluripotent Stem Cell Therapy 'Altering the muscle environment to influence stem cell behaviour' at The University of Minnesota** is looking at regenerating muscle in Duchenne patients with stem cells. Stem cells are a potentially exciting approach to generate new healthy muscle in patients with Duchenne. The stem cells we are looking at are called human induced pluripotent stem cells (iPSCs). These cells replace the diseased muscle tissue with stem cells that can create healthy myofibers which are able to regenerate. The aim of this project is to produce and test these stem cells to get the preclinical data required to progress to a clinical trial. This project has proved highly successful; this study involves phase 1 human clinical trial testing the safety and tolerability of stem cells which have proven to contribute to skeletal muscle regeneration in dystrophic mice. The team have now opened this study for recruitment and are actively seeking potential study participants.

- **FOR DMD PhD Post – Dr. Michela Guglieri, University of Newcastle** – the funding provided allowed for the analysis of the FOR DMD trial, which was a double, blind, controlled study designed to assess the relative effectiveness and adverse event profiles in Duchenne of the 3 most frequently prescribed corticosteroid regimes (daily prednisone, daily deflazacort and intermittent 10 days on 10 days off). The project led to 4 publications in high impact scientific journals and the key outcomes were:

- Initiating steroids before age 6 improves motor trajectories over 18 months, supporting treatment no later than age 6.
- Daily steroid regimes benefit ambulant (still walking) boys over 6 years old – enhancing motor performance. Older boys often start intermittent regimes to limit side effects like weight gain, but daily dosing may better maintain motor function.

...CONTINUED

Recent activities and achievements - continued

- Boys starting steroids above motor cut-off values show sustained improvement after 18 months, helping predict future motor performance.

**Alex's Wish
Trustees' Report (continued)
For The Year Ended 30 June 2025**

Financial Review

Financial Position

Income from donations and fund-raising activities for the year amounted to £348,052 (2024: £285,913). Bank interest received in the year amounted to £1,193 (2024: £1,168). Returns on investment in Reveragen £19,354 (2024: £nil)

Expenditure incurred is as shown on the detailed statement of financial activities and included: expenditure on fund-raising activities which amounted to £53,737 (2024: £49,842).

Overheads include payments for administrative services and the management of events and fundraising activities of £53,560 (2024: £79,555) and other costs relating to promotional materials, Trustee expenses, insurance, bank charges, marketing, bookkeeping, and networking events of £19,352 (2024: £25,744).

Payments towards research and clinical trials amounted to £232,989 (2024: £113,000). Overall, there were net incoming resources for the year of £6,161 (2024: outgoing £18,940).

Reserves Policy

The Charities SORP requires a charity to state the amount and type of financial reserves it holds, and to compare how the level of those reserves matches up to "The level of reserves the trustees feel as appropriate given their plans for the future activities of the charity". Where it falls short, the trustees need to explain what steps they are taking to rectify the situation. In this context, the charity views financial reserves as those held in its unrestricted funds, the balance of funds stood at £69,868 at the year-end (2024: £71,832).

The Trustees establish the appropriate level of unrestricted reserves (over and above those already ring-fenced for plans or known liabilities within restricted and designated Funds) by seeking to ensure that the level of the charity's 'free reserves' meets a chosen benchmark related to the budgeted expenditure for unrestricted activities. The Trustees consider the "free reserves" to be the unrestricted funds not committed or invested in tangible assets. As a result of a full and objective review of its 'free reserves' policy, considering all the risks foreseeable at that point and the charity's approach to their mitigation, the Trustees agreed on 9th February 2023 that £30,000 should be maintained as 'free reserves'. This level has continued to be reviewed for adequacy and robustness to ensure the Charity maintains adequate finances to meet day-to-day operating costs, and we will continue to review this over the coming months. As of 30 June 2025, the Charity's "free reserves" stood at £69,868 (2024: £71,832), resulting in a surplus of £39,868 (2024: surplus of £41,832) when compared with the current benchmark, calculated as £30,000.

Structure, Governance and Management

Governing Document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

Trustee Selection Methods

Trustees will be recruited through recommendations and social media, at our events and through word of mouth. Those expressing an interest will, in the first instance, be met by the Charity Founder, given an overview of the organisation, and encouraged to apply. The Chair and Co-Chair trustees will examine the applications against the most recent skills audit, produce a short list, and invite those on it to submit their references and then attend an interview; the Chair and Co-Chair will conduct the interviews, and make recommendations to the Board. At its next meeting, the Board will review these recommendations, and either ratify or reject. Successful applicants will be asked to complete and sign the declaration of interest form, sign a declaration that they are eligible to serve as a trustee; and agree to the code of conduct. They will then become a trustee of the Board.

**Alex's Wish
Trustees' Report (continued)
For The Year Ended 30 June 2025**

Organisational structure

The organisation is a charitable company limited by guarantee, incorporated on 22 June 2012. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association. In the event of the company being wound up members are required to contribute an amount not exceeding £1.

The body responsible for management of the Charity is the Board of Trustees of Alex's Wish. The Board meets monthly (and at least ten times per year). The charity's constitution is set out in the Articles of Association, and all Trustees have agreed to this. New Trustees are appointed by the existing Board of Trustees. Trustees give up their time freely and no Trustee remuneration was paid in this year. Details of Trustee expenses and related party transactions are disclosed in the accounts. Trustees are required to disclose all relevant interests and to withdraw from decisions where a conflict of interest arises. None of the Trustees have any interests with the pharmaceutical industry.

We regularly review our stated aims, objectives, and activities to ensure we are working toward our stated purposes. We have referred to the guidance contained in the Charity Commission's general guidance on public benefit under the Charities Act 2011 when setting and reviewing our aims and objectives and in planning our future activities. All our charitable activities focus on improving the lives of those with Duchenne Muscular Dystrophy.

Risk management

The Trustees continue to review the major strategic, business, and operational risks which the charity faces and confirm that systems are in place to enable regular reports to be produced so that the necessary steps can be taken to lessen these risks. In assessing risk, the Trustees recognise that some areas of the work require the acceptance and management of risk if the charity is to achieve its objectives.

Reference and Administrative Details

Trustees

Mr R A Copson (appointed 14/03/2025)
Mr C R Everard
Mr A R Hallam
Mrs E J Hallam
Mr S D Jesrani
Mr S G Masters (appointed 08/05/2025)
Ms A L Slack
Mrs A K Iqbal (resigned 30/04/2025)
Mr W Hazlerigg
Miss S Merrill (appointed 26/02/2026)

Charity Number

1148845

Company Number

08116159

Registered Office

21 New Walk
Leicester
LE1 6TE

Independent Examiner

J Petha FCCA
Sturgess Hutchinson
Chartered Certified Accountants
21 New Walk
Leicester
LE1 6TE

Scientific Advisory Board

We work closely with Duchenne UK as their Charity Partner and as such, majority of the projects we fund are co-funded alongside them.

All projects put forward to us for potential funding go through their rigorous Scientific Advisory Board, which is made up of some of the world's leading experts in Duchenne Muscular Dystrophy.

They bring with them a wide range of essential skills and knowledge bases, including scientific, clinical and drug discovery and development. When scientists come forward with their ideas for new research projects, it is this board who apply their experience and expertise to test these ideas, helping refine them, if necessary, in order that we can make informed decisions on funding. We want to fund great science and projects that can improve our knowledge base, treatments that can reach the clinic and improve the lives of people with Duchenne.

Duchenne UK's advisory board consists of:

- Professor Dame Kay Davies
- Dr. John Bourke
- Dr. Dada Pisconti
- Dr. Valeria Ricotti
- Professor Giovanni Baranello
- Professor Jordi Diaz Manera
- Dr. Tina Duong
- Dr. Isabelle Richard
- Dr. Carina Schey
- Professor Francesco Saverio Tedesco
- Dr. Graeme Wilkinson

Alex's Wish would like to thank its Trustees, employees, service providers and supporters for kindly giving their time and expertise to grow the charity.

Other Information

Strategic approach and plans to fulfil our charitable objectives

In the coming year we plan to:

Objective 1: To identify, fund and monitor medical research projects, clinical trials, clinical trial capacity opportunities and new technological advances.

- To receive updates on outcomes for projects funded so we can report on the impact those projects have made to help progress our mission. To report on these via our news feeds on our website, our social media platforms, e-newsletters to our supporters, through local press coverage and at our events.
- Continue to work closely with Duchenne UK as a Charity Partner. To seek out and fund new projects that fit with our mission to conquer Duchenne – to improve and extend the lives of everyone affected. Ensuring that our funds are spent effectively and in the right areas to help bring about the best chances of bringing new treatments to market.
- Increase our level of income generated each year by building relationships with our existing supporters as well as attracting new supporters to our cause.
- Continue to fund projects that will bring about effective treatments, new technologies, improve care standards, and improve clinical trial capacity in the UK for the Duchenne community and aim to give £200,000+ per annum.

Objective 2: To engage with media and our supporters to raise awareness of Duchenne Muscular Dystrophy.

- Attend the annual Horizons Conferences held by Duchenne UK to engage with other parents affected by Duchenne Muscular Dystrophy, as well as keep abreast of latest progress made in the field of Duchenne. To be actively involved in workshops and meetings alongside Duchenne UK that is focussed on improving care standards in the UK.
- Where possible, attend national events and meetings to help lobby MPs and Parliament to bring about new treatments to market as quickly as possible e.g. Vamorolone and Givinostat.
- Issue press releases and submit to the local press in the East Midlands to help raise awareness about the work we are doing and its impact on the local community / the rest of the UK and to help attract new supporters to our cause.
- Continue to send monthly updates to our supporters via e-newsletters, add newsworthy content to our website and regularly post and grow our supporter base across our social media platforms.
- Organise Supporter events including our annual Spring Launch and our Autumn Lunch to keep in touch with our supporters and guests about the vital work that we do, and how they can continue to help us.
- Continue to attend networking events within the region to build new and foster existing relationships and attract new supporters to our cause and arrange 121's with business supporters on how we can collaborate and foster relationships.
- Continue to speak at community and business events where opportunities to arise.

Objective 3: Income Generation through our flagship events, supporter events and fundraising activities.

- Organise and build on our flagship events: Annual Charity Golf Day, Supercars Day, Charity Football Tournament, Charity Grand Prix event, Annual Fundraising Ball and The Big Christmas Give campaign. Our focus is on generating an income and covering costs and providing a fun and enjoyable fundraising experience for our supporters.
- Support other organisations, groups and individuals who have decided to organise their own events in support of our cause, providing resources and time to support them achieve their fundraising goals.

...CONTINUED

**Alex's Wish
Trustees' Report (continued)
For The Year Ended 30 June 2025**

Strategic approach and plans to fulfil our charitable objectives - continued

- To attract supporters to take part in the London Marathon, walking and running events, challenge events e.g., zipwire challenges, skydiving, loop the loop aerobic displays, wing walks, and abseil challenges and to raise as much money as they can doing so, by providing them with the tools and encouragement to do so.
- Retain our existing regular giving supporters and develop new initiatives to grow our regular giving supporter base, through our 'Be More Alex' £7 a month regular giving campaign, our Business Community £75 a month regular subscription in exchange for business benefits such as organising local networking events to bring the local business community together.
- Continue to support businesses who donate a percentage of their income to us every single month and look to attract like-minded businesses.
- We aim to work within a 30:70 ratio of cost vs. income received from an event to ensure that 70% of what we raise from our events overall goes directly to fund projects to further our mission. We would like to attract more capital through corporate sponsors to cover most/if not all our event costs to help improve this ratio further. We have been successful in attracting corporate sponsors and will continue to build on those relationships.
- Majority of our income raised has been through hosting our own events. Our aim is to continue working with local businesses to take Alex's Wish on as their chosen charity and organise their own events and consider Alex's Wish as their Charity of the Year. This means that 90%+ of the money they give to us as a Charity goes directly to fund projects to further our mission as they do not incur the expenditure that our own fundraising activities require.
- Continue to work with charitable foundations who have kindly supported our work, as well as other local charitable groups, to source additional income. We are now outsourcing this important work to an expert in this field to help us identify and approach new trusts and foundation opportunities. We have seen success in this field and hope to continue to find more success as we diversify our income streams.
- Form strategic alliances and partnerships with organisations such as local sporting clubs, colleges, schools, and corporate businesses.
- We hope in the future to launch a podcast to further our reach and attract new audiences to our cause.

Statement of Trustees' Responsibilities

The trustees (who are also the directors of Alex's Wish for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statement unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing the financial statements the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgments and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The trustees are responsible for keeping adequate accounting records which disclose with reasonable accuracy at anytime the financial position of the charitable company and to enable them to ensure that the accounts comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**Alex's Wish
Trustees' Report (continued)
For The Year Ended 30 June 2025**

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Small Company Rules

This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

The trustees' report was approved by the board of trustees and signed on its behalf by:



Mrs E J Hallam

Trustee
12/03/2026

Alex's Wish
Independent Examiner's Report to the Trustees of Alex's Wish
For The Year Ended 30 June 2025

I report to the charity trustees on my examination of the accounts of the Company for the year ended 30 June 2025.

Responsibilities and Basis of Report

As the charity trustees of the Company (and also its directors for the purposes of company law), you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ("the 2006 Act").

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent Examiner's Statement

Since the Company's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of The Association of Chartered Certified Accountants, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



J Petha FCCA
12/03/2026
Sturgess Hutchinson
Chartered Certified Accountants
21 New Walk
Leicester
LE1 6TE

Alex's Wish
Statement of Financial Activities (including Income and Expenditure Account)
For The Year Ended 30 June 2025

				2025	2024
		Unrestricted funds	Restricted funds	Total funds	Unrestricted funds
	Notes	£	£	£	£
INCOME AND ENDOWMENTS FROM:					
Donations and legacies	3	78,958	43,125	122,083	37,644
Charitable activities:					
Fundraising activities		225,969	-	225,969	248,269
Investments	4	1,193	-	1,193	1,168
Other	5	19,354	-	19,354	-
		<u>325,474</u>	<u>43,125</u>	<u>368,599</u>	<u>287,081</u>
EXPENDITURE ON:					
Raising funds	6	(2,800)	-	(2,800)	-
Charitable activities:	6				
Expenditure on charitable events		(53,737)	-	(53,737)	(49,842)
Administrative services		(53,560)	-	(53,560)	(79,555)
Support costs		(19,352)	-	(19,352)	(25,744)
Separate material item of expenditure		(197,989)	(35,000)	(232,989)	(113,000)
		<u>(327,438)</u>	<u>(35,000)</u>	<u>(362,438)</u>	<u>(268,141)</u>
NET INCOME		<u>(1,964)</u>	<u>8,125</u>	<u>6,161</u>	<u>18,940</u>
NET MOVEMENT IN FUNDS		<u>(1,964)</u>	<u>8,125</u>	<u>6,161</u>	<u>18,940</u>
RECONCILIATION OF FUNDS:					
Total funds brought forward		71,832	-	71,832	52,892
TOTAL FUNDS CARRIED FORWARD	14	<u>69,868</u>	<u>8,125</u>	<u>77,993</u>	<u>71,832</u>

The notes on pages 21 to 26 form part of these financial statements.

**Alex's Wish
Balance Sheet
As At 30 June 2025**

		Unrestricted funds	Restricted funds	2025 Total funds	2024 Total funds
	Notes	£	£	£	£
CURRENT ASSETS					
Debtors	11	20,639	-	20,639	16,083
Cash at bank and in hand		68,857	8,125	76,982	68,138
		<u>89,496</u>	<u>8,125</u>	<u>97,621</u>	<u>84,221</u>
Creditors: Amounts Falling Due Within One Year	12	<u>(19,628)</u>	<u>-</u>	<u>(19,628)</u>	<u>(12,389)</u>
NET CURRENT ASSETS (LIABILITIES)		<u>69,868</u>	<u>8,125</u>	<u>77,993</u>	<u>71,832</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>69,868</u>	<u>8,125</u>	<u>77,993</u>	<u>71,832</u>
NET ASSETS		<u>69,868</u>	<u>8,125</u>	<u>77,993</u>	<u>71,832</u>
FUNDS OF THE CHARITY					
Restricted Funds				8,125	-
Unrestricted Funds				<u>69,868</u>	<u>71,832</u>
TOTAL FUNDS	14			<u>77,993</u>	<u>71,832</u>

For the year ending 30 June 2025 the charitable company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the charitable company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

On behalf of the board



Mrs E J Hallam

Trustee
12/03/2026

The notes on pages 21 to 26 form part of these financial statements.

Alex's Wish
Notes to the Financial Statements
For The Year Ended 30 June 2025

1. General Information

Alex's Wish is a company limited by guarantee, incorporated in England & Wales, registered number 08116159 and registered charity number 1148845. The registered office is 21 New Walk, Leicester, LE1 6TE.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)", Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

The charitable company is a Public Benefit Entity as defined by FRS 102.

2.2. Incoming Resources

All income is recognised in the statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

2.3. Resources Expended

Liabilities are recognised as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefit will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost relating to that category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

2.4. Leasing and Hire Purchase Contracts

Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to the statement of financial activities as incurred.

2.5. Cash and Cash Equivalents

Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks, other short-term highly liquid investments that mature in no more than three months from the date of acquisition and are readily convertible to a known amount of cash with insignificant risk of change in value, and bank overdrafts.

2.6. Taxation

The charity is exempt from tax as all its income is charitable and applied for charitable purposes.

2.7. Pensions

The charitable company operates a defined pension contribution scheme. Contributions are charged to the Statement of Financial Activities as they become payable in accordance with the rules of the scheme.

3. Income from Donations and Legacies

Alex's Wish
Notes to the Financial Statements (continued)
For The Year Ended 30 June 2025

	Unrestricted funds £	Restricted funds £	2025 Total funds £
Donations and gifts	78,958	-	78,958
Grants	-	43,125	43,125
	<u>78,958</u>	<u>43,125</u>	<u>122,083</u>
			2024
	Unrestricted funds £	Restricted funds £	Total funds £
Donations and gifts	37,644	-	37,644
Grants	-	-	-
	<u>37,644</u>	<u>-</u>	<u>37,644</u>

4. Investment Income

	2025 Unrestricted funds £	2024 Unrestricted funds £
Bank interest receivable	<u>1,193</u>	<u>1,168</u>

5. Other Income

	2025 Unrestricted funds £	2024 Unrestricted funds £
Royalty, licence and similar receivables	<u>19,354</u>	<u>-</u>

Alex's Wish
Notes to the Financial Statements (continued)
For The Year Ended 30 June 2025

6. Analysis of Expenditure

	2025		
	Activities undertaken directly	Support costs (see note 7)	Total
	£	£	£
Raising funds	2,800	-	2,800
Expenditure on charitable events	53,737	-	53,737
Administrative services	-	53,560	53,560
Support costs	-	19,352	19,352
	<u>56,537</u>	<u>72,912</u>	<u>129,449</u>

	2024		
	Activities undertaken directly	Support costs (see note 7)	Total
	£	£	£
Expenditure on charitable events	49,842	-	49,842
Administrative services	-	79,555	79,555
Support costs	-	25,744	25,744
	<u>49,842</u>	<u>105,299</u>	<u>155,141</u>

7. Support Costs

	2025		
	Administrative services	Support costs	Total
	£	£	£
Employee costs	53,560	1,848	55,408
Premises expenses	-	1,945	1,945
General administration	-	15,559	15,559
	<u>53,560</u>	<u>19,352</u>	<u>72,912</u>

	2024		
	Administrative services	Support costs	Total
	£	£	£
Employee costs	79,555	2,841	82,396
Premises expenses	-	7,140	7,140
General administration	-	15,763	15,763
	<u>79,555</u>	<u>25,744</u>	<u>105,299</u>

Alex's Wish
Notes to the Financial Statements (continued)
For The Year Ended 30 June 2025

8. Independent Examiner's Remuneration

	2025	2024
	£	£
Independent examination of the financial statements	2,340	2,340
Other assurance services	-	-
Tax advisory services	-	-
Other financial services	-	-
	<u>2,340</u>	<u>2,340</u>

9. Staff Costs

Staff costs were as follows:

	2025	2024
	£	£
Wages and salaries	52,357	77,943
Other pension costs	1,203	1,612
	<u>53,560</u>	<u>79,555</u>

No employees received employee benefits (excluding employer pension costs) for the reporting period of more than £60,000.

10. Average Number of Employees

Average number of employees during the year was: 2 (2024: 3)

11. Debtors

	2025	2024
	£	£
Due within one year		
Trade debtors	9,265	2,165
Other debtors	11,374	13,918
	<u>20,639</u>	<u>16,083</u>

12. Creditors: Amounts Falling Due Within One Year

	2025	2024
	£	£
Trade creditors	(1)	-
Other creditors	-	409
Accruals and deferred income	19,629	11,980
	<u>19,628</u>	<u>12,389</u>

Alex's Wish
Notes to the Financial Statements (continued)
For The Year Ended 30 June 2025

13. Pension Commitments

The charitable company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the charitable company in an independently administered fund.

During the year the charge to the statement of financial activities in respect of defined contribution schemes was £1,203 (2024: £1,612).

At the balance sheet date contributions of £0 (2024: £409) were due to the fund and are included in creditors.

14. Movement in Funds

	As at 1 July 2024	Income	Expenditure	As at 30 June 2025
	£	£	£	£
Unrestricted funds				
General:				
General unrestricted fund	71,832	325,474	(327,438)	69,868
Restricted funds				
The Brothers Trust	-	35,000	(35,000)	-
The D'Oyly Carte Charitable Trust	-	6,125	-	6,125
The Hospital Saturday Fund	-	2,000	-	2,000
Total restricted funds	-	43,125	(35,000)	8,125
Total funds	71,832	368,599	(362,438)	77,993

	As at 1 July 2023	Income	Expenditure	As at 30 June 2024
	£	£	£	£
Unrestricted funds				
General:				
General unrestricted fund	52,892	287,081	(268,141)	71,832
Total funds	52,892	287,081	(268,141)	71,832

15. Transactions with Trustees

During the year the expenses reimbursed to the trustees or paid directly to third parties were as follows:

Alex's Wish
Notes to the Financial Statements (continued)
For The Year Ended 30 June 2025

	2025	2024
	£	£
Travel	930	1,367

16. Related Party Disclosures

There have been no related party transaction in the reporting period that require disclosure, except for those disclosed in the Transactions with Trustees note.

17. Company limited by guarantee

The company is limited by guarantee and has no share capital.

Every member of the company undertakes to contribute to the assets of the company, in the event of a winding up, such an amount as may be required not exceeding £1.

Alex's Wish
Detailed Statement of Financial Activities (including Income and Expenditure Account)
For The Year Ended 30 June 2025

	2025	2024
	Total funds	Total funds
	£	£
INCOME AND ENDOWMENTS FROM:		
Donations and legacies		
Donations and gifts	78,958	37,644
Grants	43,125	-
	<u>122,083</u>	<u>37,644</u>
Charitable Activities:		
Fundraising activities		
Fundraising activities	225,969	248,269
	<u>225,969</u>	<u>248,269</u>
Investments		
Bank interest receivable	1,193	1,168
	<u>1,193</u>	<u>1,168</u>
Other		
Royalties and similar receivables	19,354	-
	<u>19,354</u>	<u>-</u>
	<u>368,599</u>	<u>287,081</u>
EXPENDITURE ON:		
Raising funds		
Trusts and foundations	(2,800)	-
	<u>(2,800)</u>	<u>-</u>
Charitable Activities:		
Expenditure on charitable events		
Annual Golf Day	(5,960)	(4,794)
Annual Fundraising Ball	(17,539)	(26,199)
Our Business Community	(164)	(355)
London Marathon	(480)	(2,592)
Supercars Charity Event	(7,262)	(4,778)
'Be More Alex' regular giving campaign	(530)	(481)
Abseil Charity Event	(1,059)	(1,272)
AGM / Annual Supporters Thank You Lunch	(3,406)	(3,774)
Miss Great Britain Finals Event	(568)	(1,025)
Football Event	(1,132)	(1,088)
Loop the Loop Challenge with AeroSparx	-	(1,153)
Other sundry event costs	(408)	-
Big Give Christmas Challenge	-	(60)
Fashion Show	(163)	-

...CONTINUED

Alex's Wish
Detailed Statement of Financial Activities (including Income and Expenditure Account) (continued)
For The Year Ended 30 June 2025

Spring Launch	(31)	(1,247)
Grand Prix Event	(93)	(110)
Kazoo Pink Ball	-	(914)
Wing Walk	(4,888)	-
Flat Gin Run	(12)	-
London to Paris Charity Bike Ride	(7,684)	-
Owning It - 'The Power of Resilience' talks	(2,358)	-
	<u>(53,737)</u>	<u>(49,842)</u>
Administrative services		
Wages	(52,357)	(77,943)
Employers pensions	(1,203)	(1,612)
	<u>(53,560)</u>	<u>(79,555)</u>
Support costs		
Staff training and welfare	(783)	(995)
Travel and subsistence	(1,065)	(1,846)
Rent	(1,945)	(7,140)
Computer software, consumables and maintenance	(3,921)	(3,690)
Office equipment	(35)	(713)
Insurance	(636)	(864)
Postage and stationery	(1,028)	(1,349)
Business development and networking events	(1,519)	(2,063)
Promotional materials	(4,662)	(2,793)
Website and email marketing	(646)	(874)
Independent examiner's fees	(2,340)	(2,340)
Business services	(72)	(450)
Bookkeeping and legal fees	(374)	(257)
Bank charges	(326)	(370)
	<u>(19,352)</u>	<u>(25,744)</u>
Separate material item of expenditure		
Payments for medical research, clinical posts and new technologies	(232,989)	(113,000)
	<u>(232,989)</u>	<u>(113,000)</u>
	<u>(362,438)</u>	<u>(268,141)</u>
NET INCOME	<u>6,161</u>	<u>18,940</u>